PCM
ACAD icon

Prelude Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Prelude Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,511
Closed -$593K – 1121
2025
Q2 		$593K Buy
+27,511
New +$511K 0.06% 388
2024
Q1 		– Sell
-16,595
Closed -$520K – 1283
2023
Q4 		$520K Buy
16,595
+5,727
+53% +$137K 0.03% 495
2023
Q3 		$226K Buy
+10,868
New +$295K 0.01% 832
2020
Q3 		– Sell
-362
Closed -$18K – 1761
2020
Q2 		$18K Buy
+362
New +$17.4K ﹤0.01% 1404
2020
Q1 		– Sell
-884
Closed -$38K – 1370
2019
Q4 		$38K Buy
+884
New +$38.5K ﹤0.01% 1434
2019
Q3 		– Sell
-1,355
Closed -$36K – 1665
2019
Q2 		$36K Sell
1,355
-584
-30% -$14.9K ﹤0.01% 1190
2019
Q1 		$52K Buy
+1,939
New +$45.3K ﹤0.01% 1111
2014
Q1 		– Sell
-23,020
Closed -$575K – 1822
2013
Q4 		$575K Hold
23,020
– – 0.09% 302
2013
Q3 		$632K Sell
23,020
-34,980
-60% -$731K 0.1% 236
2013
Q2 		$1.05M Buy
+58,000
New +$799K 0.23% 97

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Prelude Capital Management's ACAD Position: Q3 2025 in Review

Prelude Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 27,511 shares — an estimated $593K sold.

Prelude Capital Management first reported a position in ACAD in Q2 2013 and held it in 10 quarters. The position peaked at $1.05M in Q2 2013. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Prelude Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 27,511 Acadia Pharmaceuticals shares in Q3 2025, an estimated $593K.
  • Prelude Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 10 quarters.
  • Prelude Capital Management's Acadia Pharmaceuticals position peaked at $1.05M in Q2 2013.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.